Project Title

Project ID

Start
Date

Report Deadline

ID6431

7/1/2025

22/5/2025

Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy

ID4060

6/9/2024

Givinostat for treating Duchenne muscular dystrophy in people 6 years and over

ID6323

13/06/2024

19/02/2025

Insulin icodec for treating type 2 diabetes

ID6175

30/7/2024

5/12/2024

Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer

ID6328

16/5/2024

19/07/2024

Sirolimus for treating angiofibroma from tuberous sclerosis complex in people 6 years and older

ID3990

STA 13/62/75

Risankizumab for previously treated moderately to severely active ulcerative colitis in people aged 16 and over

ID6209

STA 13/61/67

Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome or Alström syndrome

ID3947

STA 13/57/96

Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when stem cell transplant is unsuitable

ID4014

STA 13/56/08

26/05/2022

29/07/2022

Olaparib for adjuvant treatment of high-risk HER2-negative, BRCA-positive early breast cancer after chemotherapy

ID3893

STA 13/55/84

26/04/2022

29/06/2022

Project Title

Project ID

Start
Date

Report Deadline

Pulmonary artery pressure technologies for remote monitoring of chronic heart failure

DG10087

25/11/2024

12/08/2025

DAP75

DAR 13/60/09

Innovative tests for diagnosing urinary tract infections

DAP69

DAR 13/57/10

Clopidogrel genotype testing after ischaemic stroke

DAP65

DAR 13/56/20

15/07/2022

20/02/2023

Project Title

Project ID

Start
Date

Report Deadline

Multiple sclerosis (relapsing, remitting, highly active) - natalizumab and Tyruko (natalizumab biosimilar) (after disease modifying therapy)

ID6369

19/04/2024

20/11/2024

Project Title

Project ID

Start
Date

Report Deadline

Treatments for non-small-cell lung cancer

ID6234

PATT 13/60/97

24/04/2023

20/05/2024